Close Menu

NEW YORK – ArcherDx and AstraZeneca have formed a strategic collaboration to develop assays to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer, the companies said on Tuesday.

Under the terms of the agreement, Boulder, Colorado-based ArcherDx will perform exome sequencing of resected non-small cell lung cancer patient samples and generate patient-specific, research-use-only circulating tumor DNA assays.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.